Alumis vs Immuron
ALMS and IMRN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALMS and IMRN compare
Immuron keeps more of each dollar of sales as profit, with a net margin of −47.7% compared with −5845% at Alumis.
Alumis scores higher on the StockData Score (6 against 4 for Immuron), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALMS | IMRN |
|---|---|---|
| Size and price | ||
| Market cap | $725M | – |
| Share price | $5.60 | $0.875 |
| Change, 1 year | 6.9% | −45.6% |
| Change, 5 years | – | −74.6% |
| Beta (5Y) | −1.12 | 0.37 |
| Employees | 224 | 7 |
| StockData Score | ||
| Total score | 6 (better) | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 100× | – |
| P/B | 1.9× | – |
| FCF yield | −44.3% | – |
| Growth | ||
| Revenue growth (TTM) | – | 5.9% |
| Revenue growth, 5Y average | – | 121% |
| Profitability | ||
| Gross margin | – | 64.5% |
| Operating margin | −6117% | −49.9% (better) |
| Net margin | −5845% | −47.7% (better) |
| FCF margin | −4433% | −42.3% (better) |
| Return on equity | −111% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −261.7× |
| Current ratio | 5.57 | 7.26 (better) |
| Altman Z-score | −1.67 | – |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 91.3% | 0.02% |
| Held by insiders | 30.5% | 1.9% |
| Insider net buying, 12 months | $44.7M | – |
| Short interest, % of float | 12.3% | – |
Go deeper
- ALMS stock overview
- ALMS income statement
- ALMS valuation and score
- IMRN stock overview
- IMRN income statement
- IMRN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.